Clinical Trials

Ocular Therapeutix announces topline results of phase 3 trial of dextenza for treatment of ocular itching associated with allergic conjunctivitis

Ocular Therapeutix announced topline results from its Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis (AC).

Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Novartis has unveiled plans to begin a phase III clinical study to evaluate canakinumab, an interleukin (IL)-1β blocker, in patients with COVID-19 pneumonia.

Moderna announces IND submitted to US FDA for phase 2 study of mRNA-1273 against novel coronavirus

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2) to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Verastem Oncology announces preliminary data from investigator-initiated study highlighting clinical activity of RAF/MEK and FAK combination in KRAS mutant tumours

Verastem announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.

Lynparza delivers OS benefit in PROfound trial in prostate cancer

AstraZeneca and Merck said that their co-developed cancer drug Lynparza (olaparib) demonstrated overall survival (OS) benefit in a phase 3 trial in a certain patient population with prostate cancer.

AstraZeneca, Saint Luke’s Mid America Heart Institute begin COVID-19 trial with Farxiga

AstraZeneca, along with the Saint Luke’s Mid America Heart Institute, has commenced a phase III DARE-19 study with Farxiga (dapagliflozin) in COVID-19 patients.

Emergex signs agreement with George Mason University for highly pathogenic RNA virus studies

Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.

Hope Biosciences announces third FDA-approved clinical trial for COVID-19

Hope Biosciences announces FDA approval on their third clinical trial for COVID-19.

Opdivo, Yervoy combo meets primary endpoint in phase 3 malignant pleural mesothelioma trial

Bristol-Myers Squibb (BMS) said that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) met the primary endpoint of a phase 3 trial in previously untreated malignant pleural mesothelioma (MPM).